Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

October 15, 2026

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Performance

52-Week Range 42.3% below 52-week high

21.63

16.2452W Low 37.5052W High

1 Week 5.9% below 1-week high

19.071W Low 22.981W High

Legend Biotech Corporation - American Depositary Shares (LEGN) traded between $16.24 and $37.50 over the past 52 weeks and last traded at $21.63, 42.3% below its 52-week high. Over the past week it ranged between $19.07 and $22.98.

Past 12 Months

+6.1%

+16.5%

+13.8%

-18.4%

+0.6%

-32.7%

1W +$1.24

1M +$3.06

3M +$2.62

6M -$4.87

YTD +$0.12

1Y -$10.50

LEGN was -32.7% over the past year, -18.4% over six months, +0.6% year to date, +6.1% in the last week.

12 Months vs Market

LEGN

-32.7%

DIA

+9.2%

SPY

+10.6%

QQQ

+9.2%

IWM

+13.8%

Over the past 12 months LEGN returned -32.7% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.6%, QQQ (Nasdaq 100) +9.2% and IWM (Russell 2000) +13.8%.

Volume & Liquidity 0.00× 3-mo avg

Today 1,152 3-mo avg 2.2M

2.3M

2.0M

2.2M

2.5M

YTD

2.4M

LEGN most recently traded 1,152 shares against a 3-month average daily volume of 2.2M.

More News

October 01, 2026

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

September 25, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

September 15, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

September 10, 2026

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 01, 2026

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Legend Biotech Q2 Earnings Call Highlights ↗

August 11, 2026

Via MarketBeat

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

August 11, 2026

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

July 28, 2026

Legend Biotech Announces CEO Transition

July 27, 2026

2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗

June 27, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

June 23, 2026

From Calidi Biotherapeutics, Inc

Legend Biotech Corporation Announces Pricing of Public Offering

June 17, 2026

Legend Biotech Corporation Announces Proposed Public Offering

June 17, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 15, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14, 2026

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Keep an eye on the top gainers and losers in Tuesday's session. ↗

June 02, 2026

Via Chartmill

June 02, 2026

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

June 01, 2026

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗

May 31, 2026

Via MarketBeat

Legend Biotech Announces Presentations at ASCO 2026

May 21, 2026

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗

May 17, 2026